Concurrent chemoradiotherapy using gemcitabine and nedaplatin in recurrent or locally advanced head and neck squamous cell carcinoma

Table 3 Adverse event (n = 24)

Adverse events		Grade
	1	2	3	4	1-4	3-4
Hematologic	2	5	7	11	24 (100%)	18 (75%)
Leukopenia	1	5	14	4	24 (100%)	18 (75%)
Neutropenia	7	4	9	1	21 (87.5%)	10 (41.7%)
Thrombocytopenia	6	3	6	7	22 (91.7%)	13 (54.2%)
Anemia	10	10	4	0	24 (100%)	4 (16.7%)
Mucositis	0	4	2	15	21 (87.5%)	17 (70.8%)
Fatigue	10	9	0	0	19 (79.2%)	0 (0%)
Nausea	2	10	0	0	12 (50%)	0 (0%)
Pain	1	8	3	0	12 (50%)	3 (12.5%)
Infection	4	6	2	0	12 (50%)	2 (8.3%)
Electrolyte disturbance	6	2	4	0	12 (50%)	4 (16.7%)
Dermatitis	8	1	0	2	11 (45.8%)	2 (8.3%)
Constipation	10	2	0	0	12 (50%)	0 (0%)
Hemorrhage	1	0	2	1	4 (16.7%)	3 (12.5%)
Hepatotoxicity	14	4	1	0	19 (79.2%)	1 (4.2%)
Renal toxicity	2	0	0	0	2 (8.3%)	0 (0%)
Cardiotoxicity	0	0	2	4	6 (25%)	6 (25%)
Xerostomia	4	0	0	0	4 (16.7%)	0 (0%)
Neuropathy	5	1	0	0	6 (25%)	0 (0%)